In line, the first evaluations of B7-H3-targeting immunotherapeutics in clinical studies like anti-B7-H3 antibodies and B7-H3 CAR-T cells did not reveal any unbearable toxicity and off-tumor effects against healthy B7-H3 expressing cells (58, 62). Here, CD276 is linked to neoplasm.